Real-world data of immune-related adverse events in lung cancer patients receiving immune-checkpoint inhibitors
SCLC histology and PDL1 positivity were associated with irAEs, and the occurrence of irAEs showed no impact on survival in LC patients. Future studies are required to validate the findings.
Authors
- Susan K. Parsons (ORCID: https://orcid.org/0000-0003-0282-6490)
- Yu Cao (ORCID: https://orcid.org/0000-0002-2009-4556)
- Anastasia Gurinovich (ORCID: https://orcid.org/0000-0001-9808-9397)
- Lori Pai
- Stacey Pan (ORCID: https://orcid.org/0009-0004-9164-2160)
- Yana Salei
- Margaret M. Byrne (ORCID: https://orcid.org/0000-0003-1007-9288)
- Xiao Hu (ORCID: https://orcid.org/0000-0001-9036-8455)
- Angie Mae Rodday (ORCID: https://orcid.org/0000-0002-8671-3401)
- Jeffrey H. Lin (ORCID: https://orcid.org/0000-0002-2518-6863)
Institutions
- Tufts Medical Center (US)
- University of Iowa Hospitals and Clinics (US)
- MaineHealth (US)
Publication Details
- Journal
- Immunotherapy
- Published
- 2025-03-24
- DOI
- https://doi.org/10.1080/1750743x.2025.2488728
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- National Institutes of Health
- National Center for Advancing Translational Sciences